Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Xarelto

Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Xarelto

Important safety information on the treatment of patients with antiphospholipid syndrome (APS) and the use of rivaroxaban (Xarelto®) Possible increased risk for recurrent thrombotic events

2019 Aug

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance